Medication info
Luluca Capsule 75 mg (Pregabalin)

Luluca Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Joongheon Pharm Co., Ltd.
Appearance
A hard capsule with a brown-red upper part and a white lower part, containing a white to light yellow powder.
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 201802678 · Approved 2018.06.27 · Insurance code 053300340

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single doseb TID=total daily dose administered in 3 divided doses BID=total daily dose administered in 2 divided doses QD=administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: A supplemental dose refers to an additional dose administered once. No dose adjustment is necessary in patients with hepatic impairment. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Joongheon Pharm Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • partial seizures
  • fibromyalgia
View approved original text

This medicine is used in adults for the treatment of peripheral and central neuropathic pain. It also assists in the management of partial seizures in patients with epilepsy, alleviating symptoms. It helps improve pain and discomfort by treating fibromyalgia. Overall, this medication is used for the relief of various neuropathic pains and seizure symptoms.

How to take

Adult dose

This medicine is administered orally as pregabalin in 2 divided doses per day, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Depending on the response and tolerability in each patient, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg per day. The starting dose is 75 mg twice daily (150 mg per day), and, based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over at least 1 week. Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. In patients receiving hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25-100, single doseb TID=total daily dose administered in 3 divided doses BID=total daily dose administered in 2 divided doses QD=administered once daily a: The total daily dose (mg/day) should be divided as specified in the dosing instructions. b: A supplemental dose refers to an additional dose administered once. No dose adjustment is necessary in patients with hepatic impairment. Older adults (aged 65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so patients should be carefully monitored for depression, mood changes, and unusual behaviors during treatment. Patients with allergies to any components of this medication or certain genetic lactose intolerance disorders should not take this medication. Diabetic patients should be cautious of weight gain and changes in blood sugar levels, and may need adjustments to their blood sugar control medications. If hypersensitivity reactions such as angioedema occur, stop taking the medication immediately and consult a healthcare professional. Older adults may experience symptoms such as dizziness, drowsiness, and loss of consciousness, so special caution is advised at the start of treatment. Some patients may experience blurred vision or changes in vision; if symptoms persist, consult a doctor. When discontinuing this medication, withdrawal symptoms such as insomnia, headaches, and anxiety may occur, so abrupt cessation should be avoided. Patients with a history of drug abuse should be evaluated carefully for the potential misuse and dependence on this medication. Patients with impaired renal function may require dose adjustments. Patients with heart disease should be cautious about symptoms of heart failure when taking this medication. The risk of drowsiness or respiratory depression may be increased when taken with other central nervous system depressants or alcohol, so caution is advised. Pregnant women should avoid taking this medication, especially in the early stages of pregnancy, due to the risk of fetal malformation, and women of childbearing age should use effective contraception. Lactating women should consider stopping breastfeeding or discontinuing the medication, as it may transfer into breast milk and affect the infant. Be cautious of the risk of accidents due to dizziness or drowsiness when driving or operating machinery after taking this medication. In cases of overdose, confusion, drowsiness, depression, seizures, etc., may occur, and immediate medical attention should be sought. This medication should be kept out of reach of children and should not be transferred to other containers.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • periorbital edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 180 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • sadness
  • suicidal thoughts
  • pain
  • seizures
  • excessive sweating
  • misuse
  • abuse
  • dependence
  • weight gain
  • rhinitis
  • neutropenia
  • increased appetite
  • loss of appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • paraphilia
  • restlessness
  • mood swings
  • emotional lability
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • inability to inhibit
  • lack of emotion
  • ataxia
  • coordination disorders
  • balance disorders
  • memory loss
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory impairment
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech impairment
  • myoclonus
  • reduced reflexes
  • abnormal movement
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • activity tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disorders
  • loss of taste
  • writing impairment
  • diplopia
  • vertigo
  • hyperacusis
  • first-degree atrioventricular block
  • tachycardia
  • bradycardia
  • pulsatile tachycardia
  • arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • incontinence
  • decreased urine
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • altered sensation
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue edema
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis
  • affective disorder
  • drowsiness
  • altered state of consciousness
  • agitation
  • restlessness
  • seizures
  • shock
  • anaphylaxis-like symptoms
  • mucocutaneous syndrome
  • erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is advisable to maintain storage temperatures between 15 and 30 degrees Celsius.

Appearance and packaging

Appearance

A hard capsule with a brown-red upper part and a white lower part, containing a white to light yellow powder.

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.